spacer
home > pmps > autumn 2017 > handling hazards
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Handling Hazards

The pharmaceutical industry’s ongoing search for new medicines capable of achieving greater therapeutic activity while also reducing dosage amounts and minimising undesirable side effects has led to an intense research focus on more potent drug molecules. As a result, the number of highly potent active pharmaceutical ingredients (HPAPIs) under development over the past few years has been steadily increasing, with HPAPIs present in around a quarter of medicines in the pharma pipeline (1).

The increasing demand from the oncology sector has been driving this growth, with around 60% of HPAPIs being developed as anticancer agents (1). With HPAPIs increasingly being used to treat chronic diseases such as diabetes and heart disease, this global market is expected to be worth an estimated $34.8 billion by 2025, up from $14.4 billion in 2016, according to figures from Grand View Research (2).

Highly Potent and Challenging

As HPAPIs are able to produce greater pharmacological effects at lower concentrations, smaller amounts of the drug can be administered to patients, potentially leading to fewer side effects as well as causing less damage to healthy tissue surrounding the diseased area. Furthermore, as lower administration frequencies can be used, patient adherence to medication schemes can potentially be improved. However, the greater potency of HPAPIs also presents several additional challenges to developers and manufacturers in terms of their safe handling.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
As a qualified individual for investigational medicinal products and APIs with over 25 years’ experience within the sector, Carla Brandolini is a Senior GMP QA Specialist at Aptuit, responsible for ensuring and overseeing GMP compliance and batch release. She is also an expert in dealing with regulatory authority audits and follow-ups, as well as the management of controlled substances used for clinical and toxicological studies.

With over 20 years’ experience in the pharma industry, Jean-Francois Carniaux is a highly skilled PhD-trained scientist, whose expertise focuses on API analytical and chemistry development programmes, from early development to late clinical phase and commercial manufacture. As Director of API Development and Manufacturing for the Aptuit site in Verona, Italy, he combines technical expertise in chemical development, including solid-state chemistry and scale-up troubleshooting, with a breath of experience in project leadership and management.

As Vice President, Global Head of CMC for Aptuit, Mario Maio blends scientific knowledge with business acumen, leading his team to provide development expertise for all CMC disciplines and cGMP manufacturing. During his 25-year career, he has developed and monitored early- and late-stage formulation projects and provided strategic direction for the implementation of drug delivery systems, translating innovative ideas into products.

Starting his career in 1996 as a quality co-ordinator, Iain Rusling has gathered a wealth of skills and experience working with some of the biggest companies in the industry, leading him to become Vice President of Global Quality Management and EHS at Aptuit. Iain is an expert in quality management processes thanks to his long-standing experience in different cGMP environments, allowing him to drive initiatives, foster continuous improvement and maintain high levels of accountability throughout the entire area of responsibility.
spacer
Carla Brandolini, Jean-Francois Carniaux, Mario Maio and Iain Rusling
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Biologics Day

On 20. July 2018, Phenomenex and SCIEX will co-host a full day of seminars, providing solutions for Biologics. The series of mini-seminars presented by technical experts from both companies, will cover methods for characterisation and QC testing, troubleshooting and new trends in analysis for this industry.  
More info >>

White Papers

Transforming Temperature Data Management Practices to Reduce Labor Costs and Improve Visibility and Control

Berlinger & Co AG

There are a number of temperature monitoring database options available to the biopharma supply chain professional and choosing the right one can significantly improve workflow which will reduce administrative time. This article will provide insight into practices for improving common processes through enhanced database functionality in the areas of managing data loggers by expiry date, storing and retrieving calibration certificates and acknowledging/documenting common temperature excursion events. Additionally, it describes the unique features and benefits of the Berlinger Smartview® data management system. Smartview® is a “Software as a Service” (SaaS) platform designed to efficiently and accurately manage both workflow and data in a regulatory compliant manner (21 CRF Part 11 & Annex 11). This comprehensive temperature data management system ensures reliability, accuracy, security, accessibility, and visibility to supply chain professionals, enhancing Good Distribution Practices (GDP) of temperature sensitive shipments.
More info >>

 
Industry Events

6th Annual Single Cell Analysis Congress

8-9 November 2018, London, UK

Oxford Global is proud to present its 6th Annual Single Cell Analysis Congress taking place on 8-9 November 2018 in London.  Part of the Genomics & Synthetic Biology Series UK, the congress will bring together over 600 end users representing internationally renowned research & academic institutions, clinical research institutions, healthcare organisations as well as leading pharmaceutical and biotech companies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement